CRMD

Announcements

• Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal DiseasesOct 19, 2026

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• FDA grants Priority Review to CorMedix's supplemental NDA for Rezzayo (rezafungin) to prevent invasive fungal infectionsOct 19, 2026
• Federal appeals court upheld Cormedix's victory in Minocin patent litigationJun 8, 2026
• CorMedix reported positive topline Phase III results from the ReSPECT trial evaluating REZZAYO for prevention of invasive fungal diseasesApr 27, 2026